Re-tooled Amplyx Pharmaceuticals Inc. garnered $40.5 million in series B funding for antifungal work with APX001, a new-mechanism therapy licensed from "an established pharma company" that "for strategic reasons decided to focus on later-stage programs," CEO Mike Grey told BioWorld Today.